Novartis
Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing the evolving needs of patients worldwide through the development and manufacturing of innovative pharmaceuticals. The company focuses on a wide range of therapeutic areas, including oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic conditions. Novartis is also active in medical nutrition, providing specialized nutritional solutions for individuals with specific dietary needs. Additionally, its animal health division develops advanced medicines aimed at improving the health and welfare of pets, farm animals, and farmed fish. The Genomics Institute of the Novartis Research Foundation plays a crucial role in bridging basic science and preclinical drug discovery, employing nearly 600 scientists to enhance drug development processes. Through its diverse portfolio and commitment to research, Novartis aims to transform patient care and improve health outcomes globally.
Calypso Biotech
Acquisition in 2024
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
Alcon is a leading global company in the vision care sector, headquartered in Geneva, Switzerland. Established in 1945, it specializes in developing and manufacturing innovative medical devices and pharmaceuticals focused on eye care. The company operates in two primary segments: Vision Care and Surgical. The Vision Care segment offers a range of products, including contact lenses and ocular health solutions, with well-known brands such as Dailies, Total1, and Air Optix, capturing a significant share of the U.S. contact lens market. The Surgical segment provides essential tools and devices for ophthalmic surgeries, including intraocular lenses and advanced surgical equipment like the Centurion phacoemulsification device used in cataract procedures. After operating as a subsidiary of Novartis for nine years, Alcon became an independent public company in April 2019, continuing its commitment to delivering comprehensive eye care solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.